EUVIMEDEUVIMED entdecken
Crossref

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

John Nikitas, Clayton P Smith, Wesley R Armstrong, Vishnu Murthy, Tristan Grogan, Kevyn Clark, Jonathan Moore, Makayla Roberts, Andrea Farolfi, Robert E Reiter, Matthew B Rettig, John Shen und 6 weitere

Journal of the National Comprehensive Cancer Network · 2026

DOI: 10.6004/jnccn.2025.7102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von John Nikitas und 17 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Salvage Therapy, Adenocarcinoma, Prostatic Neoplasms, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Salvage radiotherapy (sRT) is the standard of care for biochemical recurrence of prostate cancer following radical prostatectomy (RP). In this context, prostate-specific membrane antigen (PSMA) PET/CT offers superior sensitivity and specificity for the detection of recurrent disease. We aimed to evaluate the impact of PSMA PET/CT–guided management on clinical outcomes following sRT. Patients and Methods: We retrospectively screened 5 prospective PSMA PET/CT studies conducted between 2016 and 2021. Eligible patients underwent PSMA PET/CT for restaging at first biochemical recurrence after RP, received sRT, and had ≥24 months of follow-up. Progression-free survival (PFS), freedom from distant progression, and overall survival (OS) were calculated using the Kaplan-Meier method. Adjusted hazard ratios (aHRs) for PFS were derived using Cox proportional hazards regression, adjusting for age, pre-sRT prostate-specific antigen (PSA) level, use of androgen deprivation therapy (ADT), and receipt of whole-pelvis radiotherapy (WPRT).

Results

Of the total cohort, 113 patients met the inclusion criteria. Median follow-up was 59.4 months (IQR, 47.4–69.5). Median PSA was 0.4 ng/mL (IQR, 0.3–1.1), and the median time from RP was 19.9 months (IQR, 5.6–51.8). On PSMA PET/CT, 19 (16.8%) patients were staged as TrN0M0, 32 (28.3%) as N1M0, 16 (14.2%) as M1, and 46 (40.7%) as T0N0M0 (no visible disease). ADT was administered to 76 (67.3%) patients, and 63 (55.8%) patients received WPRT. Disease progression occurred in 57 (50.4%) patients. Median PFS was 49.2 months (95% CI, 24.1–74.3), and median freedom from distant progression was 76.4 months (95% CI, 62.9–89.9). The 5-year OS rate was 97.1% (95% CI, 94.1%–100%). Receipt of WPRT was significantly associated with improved PFS among patients staged as TrN0M0 (aHR, 0.12; P =.035), whereas ADT was significantly associated with improved PFS in patients staged as N1/M1 (aHR, 0.37; P =.024).

Conclusions

In this 5-year follow-up study from an institution that was an early adopter of PSMA PET/CT, PSMA PET/CT–guided sRT was associated with favorable oncologic outcomes. Exploratory analyses suggest a potential benefit of WPRT following a positive PSMA PET/CT and of ADT in patients with N1/M1 disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salvage TherapyAdenocarcinomaProstatic NeoplasmsRadiotherapy, Image-GuidedNeoplasm Recurrence, LocalRetrospective StudiesPositron Emission Tomography Computed TomographyFollow-Up StudiesSurvival AnalysisHumansMaleMiddle AgedAgedProstatectomyLos AngelesGallium Radioisotopes

Substanzen

PSMA-11Gallium Radioisotopes

Autor:innen und Institutionen

  • 1Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
  • 2Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
  • 3Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
  • 4Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA.
  • 5Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • 6Department of Urology, University of California, Los Angeles, Los Angeles, CA.

Zitieren

APA

Nikitas, J., Smith, C. P., Armstrong, W. R., Murthy, V., Grogan, T., Clark, K., Moore, J., Roberts, M., Farolfi, A., Reiter, R. E., Rettig, M. B., Shen, J., Valle, L. F., Nickols, N. G., Steinberg, M. L., Czernin, J., Kishan, A. U., & Calais, J. (2026). Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7102

Vancouver

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, et al. Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2025.7102

BibTeX
@article{Nikitas2026,
  author = {Nikitas, John and Smith, Clayton P and Armstrong, Wesley R and Murthy, Vishnu and Grogan, Tristan and Clark, Kevyn and Moore, Jonathan and Roberts, Makayla and Farolfi, Andrea and Reiter, Robert E and Rettig, Matthew B and Shen, John and Valle, Luca F and Nickols, Nicholas G and Steinberg, Michael L and Czernin, Johannes and Kishan, Amar U and Calais, Jeremie},
  title = {Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  doi = {10.6004/jnccn.2025.7102}
}
Kostenlos starten →